Recombinant Human Thyroid Stimulating Hormone in Thyroid Remnant Ablation With 1.1 GBq 131Iodine in Low-Risk Patients

    loading  Checking for direct PDF access through Ovid



To evaluate the efficacy of recombinant human thyroid stimulating hormone [rhTSH (versus hypothyroidism)] in thyroid ablation with an activity of 1.1 GBq (30 mCi) 131I.


A total of 102 patients with thyroid cancer who fulfilled the following criteria were studied: submitted to total thyroidectomy with complete tumor resection; tumor ≤4 cm without extrathyroid invasion or lymph node metastases; negative anti-thyroglobulin (anti-Tg) antibodies. Thirty-two patients (group A) received 0.9 mg of rhTSH for 2 consecutive days followed by 131I administration and 70 patients (group B) were prepared by levothyroxine withdrawal for 4 weeks. The groups were similar in sex, age, and tumor characteristics.


Ablation was successful (stimulated Tg<1 ng/mL and negative diagnostic whole-body scanning and neck ultrasonography 9 to 12 mo after ablation) in 27 patients of group A (84.3%) and in 58 of group B (83%). Considering patients with Tg greater than 1 ng/mL immediately before 131I administration, the rates were 72.2% in group A and 75% in group B. In group A, the ablation rate was similar for patients who discontinued levothyroxine-T4 3 days before 131I administration and those maintained on hormone therapy. The mean follow-up was 29.6 months in group A and 55 months in group B. Stimulated Tg (after rhTSH) was undetectable in 29 patients of group A (90.6%) and in 61 of group B (87%) and 1 patient of group B presented cervical metastases at the last assessment.


Low 131I activity after rhTSH is effective for remnant ablation in patients who are at low risk of recurrence.

Related Topics

    loading  Loading Related Articles